The China Stroke Management Interventional landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook (2021-2026)
The China Stroke management report is the first-ever syndicated report that covers the market landscape, procedural and technology trends, and competitive intelligence. The report is based on exhaustive secondary research and in-depth primary research conducted with performing physicians in Interventional Radiology/Radiology, Interventional Neurology and Neurosurgery departments from level 2 and level 3 hospitals in China.
The report covers:
Endovascular therapy (EVT) interventions: for ischemic and hemorrhagic stroke.
Neuro thrombectomy devices: stent retrievers with coil or clamp, balloon guiding catheters, aspiration devices, and microcatheters.
Procedure trends: by stages of the disease, artery location, performing departments, route of access used for the intervention, and type of interventions
Insights on reimbursement such as the variance of insurance coverage for Stroke procedures across provinces and cities based on the type of insurance, physician treatment selection criteria, current and upcoming policies for diagnosis and treatment are delved into.
Physician’s brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others affecting brand usage have been covered.
Future trends such as the continued new developments in recanalization therapy in combination use of stent retrievers, balloon guiding catheters, aspiration devices such as in Solumbra technique in addition to Direct Aspiration First Pass Technique (ADAPT) and Stent Retriever Assisted Vacuum-Locked Extraction (SAVE) technique, and the focus on R&D of product pipelines including drug-eluting balloons for neuro-interventions are covered in the report. The Healthcare Reform Plan in China initiated price control on high-value medical consumables. This had an impact on neuro-interventional consumables such as coils and microcatheters.
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Chinese companies are establishing themselves as one-stop stroke treatment solution provider. Competitor activities such as NMPA approvals of Neurohawk Stent Thrombectomy Device from MicroPort and Avenir Coil system from Wallaby Medical are covered in the report.
What’s in it for you?
This report will help Stroke interventional device companies understand the Stroke intervention landscape, procedural and technology trends, and the brand perception and competitive intelligence in China.
The report is a great resource to plan your market strategy to capitalize on upcoming trends and potential disruptors in the Stroke interventional devices market.
The deliverable includes a 100+ slide MS PowerPoint report and an MS Excel-based 5-Year market forecast model. REPORT COST: 5,000 USD
Contact us below for further details regarding the exclusive data and insights in the report or for an exploratory analyst walkthrough of the report.